Loading stock data…
TXMD
$2.07+0.03 (+1.47%)
Market ClosedLast close May 1
TherapeuticsMD, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TherapeuticsMD, Inc. in the Healthcare sector is trading at $2.07. The stock is currently 30% below its 52-week high of $2.95, remaining 24.0% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why TXMD maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.07
Potential Upside
5%
Whystock Fair Value$2.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.56
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
254.16%
Volume
Today's trading volume
2,714
Recent News
TherapeuticsMD: Q3 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Wednesday reported earnings of $152,000 in its third quarter.
TherapeuticsMD: Q2 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Tuesday reported net income of $551,000 in its second quarter.
TherapeuticsMD: Q1 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Tuesday reported a loss of $653,000 in its first quarter.